Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 653 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway March 24, 2021 New on NCI’s Websites for March 2021 March 25, 2021 FDA Approves Belzutifan for Advanced Renal Cell Carcinoma January 19, 2024 Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... October 14, 2025 Load more HOT NEWS ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the...
